Partnering with other companies is of strategic importance to Abera to advance the development of our platform and vaccine candidates. Our proprietary technologies enable the discovery, development, and production of novel vaccines and immunotherapies. We are interested in partnering with companies to further develop our vaccine projects and are open for out-licensing the platform for specific targets. Whether it is a strategic alliance, licensing, or marketing agreement, Abera wishes to work closely with its partners to ensure mutual success.